SAGE Therapeutics (SAGE) Misses Q2 EPS by 13c
Tweet
Share
E-mail
Get Alerts SAGE Hot Sheet
Join SI Premium – FREE
SAGE Therapeutics (NASDAQ: SAGE) reported Q2 EPS of ($2.68), $0.13 worse than the analyst estimate of ($2.55). Revenue for the quarter came in at $2.47 million versus the consensus estimate of $2.92 million.
For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ulta Beauty lifts guidance after Q3 results beat estimates
- Elastic N.V. (ESTC) Tops Q2 EPS by 13c; offers guidance
- Ambarella (AMBA) Tops Q3 EPS by 11c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
